Investor & Analyst Update, New York, May 16th, 2016

Update on strategy and pipeline

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, will today hold an Investor & Analyst Update in New York, USA, from 12:00 to 3:00 pm ET (6:00 to 9:00 pm CET) at NY Palace Hotel, 455 Madison Ave, Spellman Room (5th Floor).

During the meeting, Hervé Brailly, Chief Executive Officer of Innate Pharma, will provide a corporate strategy update including the Company’s approaches towards becoming an integrated biopharmaceutical company.

Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will discuss Innate’s ongoing development programs, science and R&D strategy in immuno-oncology including:

• An update on the underlying science and preclinical data supporting the development of the Company’s first-in-class checkpoint antibodies targeting NK receptors;
• A description of a new NKp46 bispecific antibody platform;
• The Company’s approach to using novel antibodies for targeting the tumor microenvironment

For live webcast and replay, please go to: http://lifesci.rampard.com/20160516/reg.jsp